A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm

Trial status:Will Be Recruiting
Trial ID:
BNT211-02
NCT ID:
NCT06940804
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Will Be Recruiting

Trial Details

This study is designed to evaluate the safety, efficacy, cellular kinetics, and immunogenicity of Claudin 6 (CLDN6) Chimeric antigen receptor T cell (CAR-T) ± CLDN6 ribonucleic acid-lipoplex (RNA-LPX) in participants born male with relapsed or refractory CLDN6-positive testicular or extragonadal germ cell tumors (GCTs) after prior salvage therapy.

Medical Condition
  • Unmapped
    • Trial Drug
  • CLDN6 CAR-T
    • See more
  • CLDN6 RNA-LPX
    • Phase
    Phase 2
    Type
    Interventional
    Estimated Enrolment
    150
    Estimated Trial Date
    Jul 2025 - Jun 2042

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Male
    Healthy Volunteers
    No

    Trial Locations

    No locations found.